|
Jan 10
|
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
|
|
Jan 2
|
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants
|
|
Jan 2
|
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
|
|
Dec 29
|
Biotech Stocks Were Tanking. The Cure? M&A.
|
|
Dec 29
|
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
|
|
Dec 29
|
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
|
|
Dec 28
|
Buy AstraZeneca Stock. It Looks Much Better Going Into 2024.
|
|
Dec 27
|
Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Dec 27
|
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
|
|
Dec 27
|
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
|
|
Dec 27
|
Trending tickers: Intel | Tencent | RayzeBio | Astrazeneca
|
|
Dec 27
|
16 Most Promising Dividend Stocks According to Analysts
|
|
Dec 27
|
PRESS DIGEST-British Business - Dec 27
|
|
Dec 22
|
Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod
|
|
Dec 22
|
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate
|
|
Dec 22
|
These 3 Big Pharma Stocks Are Making Big Plays With AI
|
|
Dec 22
|
Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug
|
|
Dec 22
|
WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
|
|
Dec 21
|
CORRECTED-UPDATE 2-US FDA approves Ionis-AstraZeneca's nerve disease drug
|
|
Dec 21
|
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
|